Welcome to our dedicated page for Churchill Cap X SEC filings (Ticker: CCCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Churchill Capital Corp X (CCCX) files with the U.S. Securities and Exchange Commission as a blank check company listed on Nasdaq. This SEC filings page allows investors to review the company’s regulatory documents, which are central to understanding its structure as a special purpose acquisition company and its proposed business combination with ColdQuanta, Inc. (Infleqtion).
Key filings for Churchill Capital Corp X include current reports on Form 8-K, which disclose material events. One such Form 8-K describes the Agreement and Plan of Merger and Reorganization among Churchill Capital Corp X, two merger subsidiaries, and ColdQuanta, Inc., and notes the confidential submission of a draft registration statement on Form S-4. Subsequent communications reference the filing of a joint Form S-4 that includes a preliminary proxy statement/prospectus for Churchill Capital Corp X shareholders.
Through this page, users can access the company’s registration statements, proxy materials related to the proposed transaction, and other Exchange Act reports. These documents outline the terms of the business combination, the securities to be issued, and the risk factors associated with the transaction and the combined company. They also provide details on Churchill Capital Corp X’s units, Class A ordinary shares, and warrants listed on Nasdaq.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, helping readers interpret items such as merger terms, forward-looking statements, and risk disclosures. As new filings are made available through EDGAR, they are reflected here so that investors can review the latest information on CCCX, the proposed Infleqtion merger, and any subsequent corporate actions.
Use this page to examine Churchill Capital Corp X’s 8-K reports, registration statements on Form S-4, and related proxy and prospectus materials, and to understand how the company’s SPAC structure and planned business combination are documented in its official SEC submissions.
Infleqtion, Inc. amended a Schedule 13G/A to report ownership details for certain reporting persons. The filing shows Tyler Brous beneficially owned 1,407,392 shares, representing 0.7% of common stock. The reporting persons state they ceased to be beneficial owners of more than 5% on April 23, 2026 and are no longer required to file under the higher reporting threshold.
Infleqtion, Inc. insider filings show a major restructuring by LCP Quantum investment funds associated with manager Tyler Brous. On April 23, 2026, these funds completed “other” transactions that together reclassified and distributed 30,528,914 shares of Common Stock to their own investors, pro rata and without consideration.
Because the funds distributed the shares they had held directly, the reporting persons are no longer deemed 10% owners and are no longer subject to Section 16(a) for Infleqtion securities. A related entry on April 22, 2026 shows Tyler Brous holding 1,403,922 Common shares directly after a change in the form of beneficial ownership from indirect to direct under Rule 16a-13.
Infleqtion, Inc. reported that director David B. Singer was granted stock options covering 33,928 shares of common stock at an exercise price of $12.59 per share. The options vest in full on the earlier of May 23, 2027 or the issuer's next annual stockholder meeting after April 10, 2026, subject to his continuous service. These options expire on April 10, 2036. According to the disclosure, the economic benefit of this director compensation passes to Maverick Ventures Investment Fund, L.P. through a management fee offset, and Singer disclaims beneficial ownership except to the extent of his pecuniary interest.
Infleqtion, Inc. reported that director David B. Singer received a grant of stock options covering 33,928 shares of common stock at an exercise price of $12.59 per share. The options were awarded at no cost and expire on April 10, 2036.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to Mr. Singer’s continued board service. After this grant, 33,928 derivative securities of this type are reported as beneficially owned indirectly.
Infleqtion, Inc. director David B. Singer received a grant of stock options covering 33,928 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036.
These options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to his continuous service under the company’s 2026 Equity Incentive Plan. Vesting may accelerate under the Non-Employee Director Compensation Policy.
Infleqtion, Inc. director Dawn Clawson Meyerriecks received a grant of stock options as equity compensation. She was awarded 33,928 options to buy Infleqtion common stock at an exercise price of $12.59 per share, expiring on April 10, 2036. Following this grant, she holds 33,928 derivative securities linked to common stock.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting after April 10, 2026, subject to her continued service under the company’s 2026 Equity Incentive Plan and any acceleration provisions in the Non-Employee Director Compensation Policy.
Infleqtion, Inc. director Kristina M. Johnson received a grant of stock options covering 22,619 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036. After this grant, she holds 22,619 derivative securities of this type.
The options vest in full on the earlier of May 23, 2027 or the company’s next annual stockholders’ meeting following April 10, 2026, subject to her continuous service under Infleqtion’s 2026 Equity Incentive Plan and its Non-Employee Director Compensation Policy.
Infleqtion, Inc. director James Eric Bjornholt received a grant of stock options covering 22,619 shares of common stock. The options have an exercise price of $12.59 per share and expire on April 10, 2036. They vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, subject to his continuous service under the company’s 2026 Equity Incentive Plan.
Infleqtion, Inc. director Catherine P. Lego received a grant of stock options as part of her compensation. She was awarded 22,619 options to buy Infleqtion common stock at an exercise price of $12.59 per share, expiring on April 10, 2036.
The options vest in full on the earlier of May 23, 2027 or the date of Infleqtion’s next annual stockholder meeting following April 10, 2026, provided she maintains continuous service under the company’s 2026 Equity Incentive Plan. After this grant, she directly holds options for 22,619 shares.
Infleqtion, Inc. director James Eric Bjornholt reported receiving a grant of stock options covering 29,950 shares of Common Stock on February 13, 2026. The options have an exercise price of $13.22 per share and expire on February 12, 2036.
According to the filing, one-third of the underlying shares vest on December 21, 2026, with 1/36 of the total vesting each month thereafter, subject to his continued service. This amendment also corrects a prior scrivener’s error in the originally reported first exercisable date.